Pharmaceutical known chemically as bremelanotide is aimed at women with low sexual desire disorder or HSDD
Drug regulators in the United States have approved Vyleesi, the latest attempt to come up with a “female Viagra” for women with low sexual desire.
Vyleesi, chemically known as bremelanotide, is said to activate pathways in the brain involved in sexual desire, helping premenopausal women with hypoactive sexual desire disorder (HSDD). It has been developed by Palatin Technologies and licensed to Amag Pharmaceuticals, and is expected to be available from September through select pharmacies.
Continue reading...from The Guardian http://bit.ly/2XkMkpd
